A deep dive into Eli Lilly’s tantalizing Alzheimer’s drug data

What is that?

STAT + is STAT’s premium subscription service for coverage and in-depth analysis of biotechnology, pharmaceuticals, politics and life sciences. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific discoveries and clinical trial results, and health interruptions in Silicon Valley and beyond.

What is included?

• Daily reports and analysis
• The most comprehensive coverage in the industry by a powerful team of reporters
• Exclusive newsletters for subscribers
• Daily newsletters to inform you of the most important industry news of the day
• STAT + conversations
• Weekly opportunities to interact with our reporters and industry-leading experts in live video chats
• Exclusive industry events
• Premium access to network events only for subscribers across the country
• The best reporters in the industry
• The most trusted and well-connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.